Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Biomarin Pharmaceutical Inc Transaction History

Meag Munich Ergo, Kapitalanlagegesellschaft Mb H

$3.1 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 25, 2022	SELL	$71.72 - $91.47 $359,890 - $458,996	-5,018 Closed	0 $0
Q2 2021 Jul 16, 2021	SELL	$75.51 - $84.79 $13,969 - $15,686	-185 Reduced 3.56%	5,018 $419,000
Q1 2021 Apr 20, 2021	BUY	$74.73 - $90.69 $388,820 - $471,860	5,203 New	5,203 $393,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H, based on Form 13F filings with the SEC.

News

Stay updated on Meag Munich Ergo, Kapitalanlagegesellschaft Mb H with notifications on news.

Account